Trial 3L-23-2


A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Biological Response Modifier, Immunotherapy
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Charlean Ketchens, Coordinator, Mary Ordaz, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Niranjan Bhatt, D.M., Rabia Rehman, Coordinator, Angela Smith Bryant, Coordinator, Young-Wook Kim, Coordinator, Syed Husein, D.M., Diane Chun, Coordinator, Janet Luong, Coordinator, Liza Pizarro, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.